Saniona's partner TRC will initiate a Phase 2 study for NS2359 in cocaine addiction following grant from Dana Foundation

Saniona, a leading biotech company in the field of ion channels, announces today that the Dana Foundation has awarded the University of Pennsylvania Treatment Research Center (TRC) a grant of USD 250,000 to conduct a Phase 2 clinical trial for NS2359 for treatment of cocaine addiction. TRC expects to initiate the Phase 2 study during the first half of 2016. Today there are no approved drugs to treat cocaine addiction.

The release as fetched from its publisher. saniona.com ↗